论文部分内容阅读
目的探讨不同用药方案治疗儿童哮喘的临床疗效。方法选择98例儿童哮喘患儿为研究对象,随机分为孟鲁司特钠组、布地奈德组、对照组,分别给予孟鲁司特钠每晚5mg顿服、布地奈德气雾剂200μg/次,1次/d及还尔金5g/次,2次/d口服,12周后观察三组哮喘控制情况及肺功能改善情况,并进行比较。结果孟鲁司特钠组及布地奈德组治疗后FEV1、PEF明显增加,差异有统计学意义(P<0.05)。孟鲁司特钠组及布地奈德组控制率与对照组比较均明显升高,差异有统计学意义(P<0.01),但孟鲁司特钠组与布地奈德组之间比较差异均无统计学意义(P>0.05)。结论口服孟鲁司特钠及低剂量吸入布地奈德对控制儿童哮喘及肺功能改善疗效确切。
Objective To investigate the clinical efficacy of different drug regimens in the treatment of childhood asthma. Methods A total of 98 children with asthma were selected as study subjects and were randomly divided into montelukast sodium group, budesonide group and control group. Montelukast sodium was given 5 mg daily, budesonide aerosol 200 μg / Times, once / d and also gold 5g / times, 2 times / d orally, 12 weeks after the observation of asthma control and lung function improvement, and compared. Results The FEV1 and PEF of montelukast sodium group and budesonide group were significantly increased after treatment, the difference was statistically significant (P <0.05). The control rates in montelukast sodium group and budesonide group were significantly higher than those in control group (P <0.01), but the differences between montelukast sodium group and budesonide group were statistically significant No statistical significance (P> 0.05). Conclusions Oral montelukast sodium and low-dose inhaled budesonide are effective in controlling childhood asthma and pulmonary function.